Ginkgo Bioworks vs Personalis
Ginkgo Bioworks reported revenue of $170 million in fiscal 2025, 2.4 times Personalis' $70 million in fiscal 2025. Ginkgo Bioworks' revenue fell 25.1% in its latest year, and Personalis' fell 17.7%. Ginkgo Bioworks had an operating margin of -185.3%, against -126.4% at Personalis. Free cash flow was −$179 million at Ginkgo Bioworks and −$79 million at Personalis.
Side by side
| Ginkgo Bioworks | Personalis | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $170M | $70M |
| Revenue growth | −25.1% | −17.7% |
| Revenue growth a year, last 5 years | 17.3% | −2.4% |
| Gross margin | — | 22.6% |
| Operating margin | −185.3% | −126.4% |
| Net margin | −183.8% | −116.7% |
| Free cash flow | −$179M | −$79M |
| Free cash flow margin | −105.0% | −114.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.9% | 50.6% |
| Last close | $9.61 | $15.71 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Ginkgo BioworksPersonalis
Operating margin
Percent of revenue
Ginkgo BioworksPersonalis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ginkgo BioworksPersonalis
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ginkgo Bioworks and Personalis pages.